Home » News » Drug Sponsors » Silence Therapeutics to close U.S. operations

Silence Therapeutics to close U.S. operations

Friday, June 3, 2011

London-based Silence Therapeutics, a global RNA interference (RNAi) therapeutics company, has announced plans to close its U.S. operations in conjunction with a recent fundraising round.

The U.S. facility is scheduled to close during the third quarter of 2011. As part of the reorganization, Phil Haworth will step down as CEO once a successor is identified, as previously announced. Recruitment of a new CEO is ongoing.

Silence will continue the following drug development plans: Complete the ongoing phase I trial of Atu027 for treatment of advanced solid cancer in the second half of 2011; initiate a phase Ib trial of Atu027 in particular tumor types in mid-2012; file an IND with the FDA for Atu134 for the treatment of solid tumors in the second half of 2012; and advance pre-clinical development of Atu111 for systemic delivery to the lung for the treatment of pulmonary disease.


Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!